Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Debt (2016 - 2025)

Historic Total Debt for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $109.0 million.

  • Rhythm Pharmaceuticals' Total Debt changed N/A to $109.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.0 million, marking a year-over-year change of. This contributed to the annual value of $109.8 million for FY2024, which is 345.48% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Total Debt stood at $109.0 million.
  • Rhythm Pharmaceuticals' Total Debt's 5-year high stood at $109.8 million during Q4 2024, with a 5-year trough of $106.1 million in Q4 2023.
  • For the 3-year period, Rhythm Pharmaceuticals' Total Debt averaged around $108.8 million, with its median value being $109.5 million (2025).
  • Over the last 5 years, Rhythm Pharmaceuticals' Total Debt had its largest YoY gain of 345.48% in 2024, and its largest YoY loss of 345.48% in 2024.
  • Quarter analysis of 3 years shows Rhythm Pharmaceuticals' Total Debt stood at $106.1 million in 2023, then rose by 3.45% to $109.8 million in 2024, then decreased by 0.77% to $109.0 million in 2025.
  • Its Total Debt was $109.0 million in Q3 2025, compared to $109.8 million in Q2 2025 and $109.5 million in Q1 2025.